US OptionsDetailed Quotes
IBB250110P132000
- 0.18
- -0.05-21.74%
15min DelayClose Jan 8 16:00 ET
0.25High0.18Low
0.25Open0.23Pre Close2 Volume38 Open Interest132.00Strike Price43.00Turnover41.45%IV2.23%PremiumJan 10, 2025Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.18Extrinsic Value100Contract SizeAmericanOptions Type-0.1216Delta0.0814Gamma898.87Leverage Ratio-0.3432Theta-0.0003Rho-109.31Eff Leverage0.0121Vega
iShares Biotechnology ETF Stock Discussion
Market corrections, characterized by a significant decline in stock prices, can be unsettling for even the most seasoned investors. However, Exchange-Traded Funds (ETFs) offer a versatile toolkit to help navigate these turbulent periods.
There are a few things we need to...
What is the overall pattern of the US stock bull market over the past ten years?
People often ask me about my experience in investing in US stocks. I...
With the Fed's September meeting likely to deliver a rate decrease, the question arises: how should investors allocate assets during an interest rate cut cycle? Let's delve into the tactics and consid...
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF XBI 0.05% drop nearly 50%.
The other most-watched exchange-traded fund that tracks the biotech secto...
Buy this ETF before the biotechnology boom will come next time
M&A in Q1 alone totaled 12 deals for $19.2 bil which is close to the 10 deals for $21.9 bil in all the 1H of 2023...
But one big caveat of this chart, it doesn't include $Pfizer (PFE.US)$ 's $43 bil deal for $SGEN announced in Mar 2023 but didn't close until Dec bc of an FTC challenge,
The biggest biotech M&A deal so far this yr was $Gilead Sciences (GILD.US)$ 's $4.3 b...
Observations from $VINC (-60% AH):
1- When companies tout "strong safety profile", often means efficacy is a big fat zero
2- Phrases like "dose dependent clinical activity" set the bar low
3- "Promising" doesn't necessarily refer to SP
Stay skeptical, my friends.
Mike on biotech's correlation with interest rates:
"Biotech is essentially a call option on $iShares 20+ Year Treasury Bond ETF (TLT.US)$
Biotech bulls need inflation and rates to move lower for resumption of a real bull market.
XBI is likely to remain range-bound - or worse - until inflation convincingly moves lower.
Hopefully we can grind out reasonable returns in the meantime by buying the right stocks, but we will b...
Big Pharma’s patent cliff issue getting mainstream media attention,
Top 20 biopharma have $180 bil in sales at risk from patent expirations by 2028 according to EY,
But that estimate could prove low compared to…👇
Bloomberg Intelligence business estimates 170 drugs w/ close to $400 bil in est global sales could lose patent excl by start of next decade,
Big Pharma wants to avoid stagnant rev g...
No comment yet